Clinical trials: ASV
Hepatitis c
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
- Trial name
- NCT02762448
- Testing
- Daclatasvir+ Asunaprevir
- Sponsor
- Tainan Municipal Hospital
Ventilators, Mechanical, Intensive Care Units
Postoperative INTELLiVENT-ASV Ventilation
The aim of this study is to investigate whether postoperative ventilation with INTELLiVENT-ASV(adaptive support ventilation) in high risk patients, after cardiothoracic surgery, is as effective, more user-friendly and as safe as…
- Conditions
- Ventilators, Mechanical, Intensive Care Units, Postoperative Care
- Trial name
- POSITiVE (NCT03180203)
- Testing
- INTELLiVENT-ASV, Conventional modes
- Where
- Netherlands
- Volunteers
- 220 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Hepatitis C
The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Safety and Efficacy of DAAs (Daclatasvir+Asunaprevir) in patients with chronic hepatitis C and chronic renal failure will be assessed.
- Trial name
- NCT02580474
- Testing
- Daclatasvir plus Asunaprevir
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Myeong Jun Song
Chronic Hepatitis C
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
A study on regression of liver fibrosis assessed by transient elastography after Daclatasvir and Asunaprevir combined treatment in advanced fibrotic/cirrhotic patients with chronic hepatitis C genotype 1b Infection
- Trial name
- RELIF-C (NCT02865369)
- Testing
- Daclatasvir and Asunaprevir
- Where
- 10 sites in South Korea
- Volunteers
- 103 people
- Sponsor
- Sang Gyune Kim
Hepatitis C
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
The primary purpose of this study is to assess the effect of the Daclatasvir/Asunaprevir/BMS-791325 fixed dose combination (FDC) tablet on the pharmacokinetics of the cocktail CYP and transporter probe substrates and to assess…
- Trial name
- NCT02045966
- Testing
- Cocktail, DCV 3DAA FDC, BMS-791325
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Adaptive Servo Ventilation (ASV) in Heart Failure
Up to 60% of patients with heart failure show abnormal patterns of breathing (sleep disordered breathing (SDB)) at night which can increase the risk of recurrent admissions and have important prognostic implications.
- Trial name
- NCT02440971
- Testing
- S9-Autoset CS-A
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- St Vincent's University Hospital, Ireland
HIV-HCV
Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 180 million people infected worldwide.
- Trial name
- NCT02124044
- Testing
- Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatic Insufficiency
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.
- Trial name
- NCT01019070
- Testing
- BMS-650032
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Rationale: Chronic HCV infection is characterised by a weak HCV specific CD8+ T cell response, due to continuous pressure of high viral load.
- Trial name
- ImmunoDual (NCT02282709)
- Testing
- Daclatasvir, asunaprevir
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Foundation for Liver Research
Hepatitis C
Drug-Drug Interaction Study in Healthy Subjects
The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone
- Trial name
- NCT00904059
- Testing
- BMS-650032, BMS-790052
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism
The purpose of this study is to examine whether neurocognitive impairments experienced by patients with chronic hepatitis C virus (HCV) infection can be reversed by treating HCV, with a new combination of direct acting antiviral…
- Trial name
- HEPCOG-II (NCT02292966)
- Testing
- DCV/ASV/BCV
- Where
- 2 sites in Australia
- Sponsor
- Kirby Institute
Hepatitis C Virus Infection
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subject.
- Trial name
- NCT01718145
- Testing
- Daclatasvir, Asunaprevir, Ribavirin
- Where
- 48 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Bristol-Myers Squibb
Chronic Obstructive Pulmonary Disease
Intellivent ASV in Chronic Obstructive Pulmonary Disease Patients in the ICU
This study will evaluate the effect of a fully closed loop ventilation mode (Intellivent ASV) on the duration of ventilation compared to conventional modes in COPD patients.
- Trial name
- NCT02651935
- Testing
- Intellivent ASV
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people
- Sponsor
- Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital
Hepatitis C Infection
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.
- Trial name
- NCT01051414
- Testing
- BMS-790052, BMS-650032
- Where
- 4 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Bristol-Myers Squibb
Mechanical Ventilation
Ventilation With ASV Mode in Children
ASV mode of ventilation is an automatic mode with closed-loop control used for mechanical invasive ventilation in intubated patients. It has been studied in adult patients but not in children.
- Trial name
- NCT03930147
- Testing
- ASV ventilation
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Lausanne Hospitals
Hepatitis C Virus
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
- Trial name
- UNITY 4 (NCT02170727)
- Testing
- DCV/ASV/BMS-791325
- Where
- 20 sites in Russia, South Korea and 1 more
- Volunteers
- 199 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA < LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment…
- Trial name
- NCT01455090
- Testing
- BMS-650032, BMS-790052, BMS-791325
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Periodic Breathing, Breathing-Related Sleep Disorder
Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV
This study will determine if modified adaptive servoventilation (ASV) is as effective as the conventional ASV in treating periodic breathing.
- Trial name
- NCT01405313
- Testing
- Modified Adaptive Servoventilation Device, Conventional Adaptive Servoventilation device
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- ResMed
HCV-HIV Co-Infection
Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders
Evaluation of efficacy and tolerance to a QUadruple therapy with Asunaprevir , Daclatasvir, Ribavirin and pegylated Interferon alpha-2a, in HIV-HCV genotype 1 or 4 coinfected patients previously null responders to a standard…
- Trial name
- QUADRIH (NCT01725542)
- Testing
- Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a
- Where
- France
- Volunteers
- 75 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients…
- Trial name
- RHACE 1 (NCT02098616)
- Testing
- DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Timothy Morgan, MD